Together they aim to accelerate the development of therapies that work through RNA biology and engineered delivery methods to fix root genetic causes of disease, which Pfizer could apply to its portfolio of investigational programs.
Daniel Siegwart, Ph.D., is Director of the Program in Genetic Drug Engineering, Professor of Biomedical Engineering and Biochemistry, and a member of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern. [Photo: UT Southwestern]